Iodixanol, a new isosmotic nonionic contrast agent compared with iohexol in cardiac angiography

James A. Hill, Martin B. Cohen, William H. Kou, G. B John Mancini, Michael Mansour, Harvey Fountaine, Jeffrey A Brinker

Research output: Contribution to journalArticle

Abstract

Iodixanol, a new ratio 6 nonionic iodinated contrast agent with an osmolality equal to serum, was compared with iohexol in a randomized, double-blind, parallel study. Two hundred patients undergoing elective diagnostic cardiac angiography were randomized to iodixanol (n = 101) or iohexol (n = 99). There were no differences noted between the 2 agents in the mean changes in systolic or diastolic blood pressure or heart rate during or immediately after any angiography. However, significantly more patients had a decrease in diastolic Mood pressure of >20 mm Hg during left coronary angiography with iodixanol. The only significant differences in any electrophysiologic parameter were slightly more PR prolongation during left coronary angiography with iodixanol and more ST-segment depression with iohexol during coronary angiography. Neither was clinically significant. Injection-associated discomfort occurred with both agents, but more patients experienced moderate to severe discomfort with iohexol (52%) than with iodixanol (17%) (p <0.001). Only 1 potentially serious adverse event, ventricular fibrillation with iohexol, was considered related to contrast, and there were no differences noted between the agents. Overall, angiographic quality was equal with all angiograms being assessed as good or excellent in both groups (p = 0.885). In this low-risk population undergoing cardiac angiography, iodixanol is safe and effective without clinically important differences from iohexol. Additional studies in patients at high risk for complications should help further define the role of iodixanol in cardiac angiography.

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
JournalThe American Journal of Cardiology
Volume74
Issue number1
DOIs
StatePublished - Jul 1 1994

Fingerprint

Iohexol
Contrast Media
Angiography
Coronary Angiography
Blood Pressure
Proxy
Ventricular Fibrillation
iodixanol
Double-Blind Method
Osmolar Concentration
Heart Rate
Injections
Serum

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Iodixanol, a new isosmotic nonionic contrast agent compared with iohexol in cardiac angiography. / Hill, James A.; Cohen, Martin B.; Kou, William H.; Mancini, G. B John; Mansour, Michael; Fountaine, Harvey; Brinker, Jeffrey A.

In: The American Journal of Cardiology, Vol. 74, No. 1, 01.07.1994, p. 57-63.

Research output: Contribution to journalArticle

Hill, James A. ; Cohen, Martin B. ; Kou, William H. ; Mancini, G. B John ; Mansour, Michael ; Fountaine, Harvey ; Brinker, Jeffrey A. / Iodixanol, a new isosmotic nonionic contrast agent compared with iohexol in cardiac angiography. In: The American Journal of Cardiology. 1994 ; Vol. 74, No. 1. pp. 57-63.
@article{20ae82d668094a31be7943c4b8b5c3f5,
title = "Iodixanol, a new isosmotic nonionic contrast agent compared with iohexol in cardiac angiography",
abstract = "Iodixanol, a new ratio 6 nonionic iodinated contrast agent with an osmolality equal to serum, was compared with iohexol in a randomized, double-blind, parallel study. Two hundred patients undergoing elective diagnostic cardiac angiography were randomized to iodixanol (n = 101) or iohexol (n = 99). There were no differences noted between the 2 agents in the mean changes in systolic or diastolic blood pressure or heart rate during or immediately after any angiography. However, significantly more patients had a decrease in diastolic Mood pressure of >20 mm Hg during left coronary angiography with iodixanol. The only significant differences in any electrophysiologic parameter were slightly more PR prolongation during left coronary angiography with iodixanol and more ST-segment depression with iohexol during coronary angiography. Neither was clinically significant. Injection-associated discomfort occurred with both agents, but more patients experienced moderate to severe discomfort with iohexol (52{\%}) than with iodixanol (17{\%}) (p <0.001). Only 1 potentially serious adverse event, ventricular fibrillation with iohexol, was considered related to contrast, and there were no differences noted between the agents. Overall, angiographic quality was equal with all angiograms being assessed as good or excellent in both groups (p = 0.885). In this low-risk population undergoing cardiac angiography, iodixanol is safe and effective without clinically important differences from iohexol. Additional studies in patients at high risk for complications should help further define the role of iodixanol in cardiac angiography.",
author = "Hill, {James A.} and Cohen, {Martin B.} and Kou, {William H.} and Mancini, {G. B John} and Michael Mansour and Harvey Fountaine and Brinker, {Jeffrey A}",
year = "1994",
month = "7",
day = "1",
doi = "10.1016/0002-9149(94)90492-8",
language = "English (US)",
volume = "74",
pages = "57--63",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Iodixanol, a new isosmotic nonionic contrast agent compared with iohexol in cardiac angiography

AU - Hill, James A.

AU - Cohen, Martin B.

AU - Kou, William H.

AU - Mancini, G. B John

AU - Mansour, Michael

AU - Fountaine, Harvey

AU - Brinker, Jeffrey A

PY - 1994/7/1

Y1 - 1994/7/1

N2 - Iodixanol, a new ratio 6 nonionic iodinated contrast agent with an osmolality equal to serum, was compared with iohexol in a randomized, double-blind, parallel study. Two hundred patients undergoing elective diagnostic cardiac angiography were randomized to iodixanol (n = 101) or iohexol (n = 99). There were no differences noted between the 2 agents in the mean changes in systolic or diastolic blood pressure or heart rate during or immediately after any angiography. However, significantly more patients had a decrease in diastolic Mood pressure of >20 mm Hg during left coronary angiography with iodixanol. The only significant differences in any electrophysiologic parameter were slightly more PR prolongation during left coronary angiography with iodixanol and more ST-segment depression with iohexol during coronary angiography. Neither was clinically significant. Injection-associated discomfort occurred with both agents, but more patients experienced moderate to severe discomfort with iohexol (52%) than with iodixanol (17%) (p <0.001). Only 1 potentially serious adverse event, ventricular fibrillation with iohexol, was considered related to contrast, and there were no differences noted between the agents. Overall, angiographic quality was equal with all angiograms being assessed as good or excellent in both groups (p = 0.885). In this low-risk population undergoing cardiac angiography, iodixanol is safe and effective without clinically important differences from iohexol. Additional studies in patients at high risk for complications should help further define the role of iodixanol in cardiac angiography.

AB - Iodixanol, a new ratio 6 nonionic iodinated contrast agent with an osmolality equal to serum, was compared with iohexol in a randomized, double-blind, parallel study. Two hundred patients undergoing elective diagnostic cardiac angiography were randomized to iodixanol (n = 101) or iohexol (n = 99). There were no differences noted between the 2 agents in the mean changes in systolic or diastolic blood pressure or heart rate during or immediately after any angiography. However, significantly more patients had a decrease in diastolic Mood pressure of >20 mm Hg during left coronary angiography with iodixanol. The only significant differences in any electrophysiologic parameter were slightly more PR prolongation during left coronary angiography with iodixanol and more ST-segment depression with iohexol during coronary angiography. Neither was clinically significant. Injection-associated discomfort occurred with both agents, but more patients experienced moderate to severe discomfort with iohexol (52%) than with iodixanol (17%) (p <0.001). Only 1 potentially serious adverse event, ventricular fibrillation with iohexol, was considered related to contrast, and there were no differences noted between the agents. Overall, angiographic quality was equal with all angiograms being assessed as good or excellent in both groups (p = 0.885). In this low-risk population undergoing cardiac angiography, iodixanol is safe and effective without clinically important differences from iohexol. Additional studies in patients at high risk for complications should help further define the role of iodixanol in cardiac angiography.

UR - http://www.scopus.com/inward/record.url?scp=0028304561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028304561&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(94)90492-8

DO - 10.1016/0002-9149(94)90492-8

M3 - Article

C2 - 8017308

AN - SCOPUS:0028304561

VL - 74

SP - 57

EP - 63

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1

ER -